# Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

> **NCT05383001** · PHASE2 · WITHDRAWN · sponsor: **AIO-Studien-gGmbH**

## Conditions studied

- NSCLC Stage IV

## Interventions

- **DRUG:** combination regimen tremelimumab /durvalumab
- **DRUG:** platinum-based chemotherapy (SoC)

## Key facts

- **NCT ID:** NCT05383001
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-05-20
- **Primary completion:** 2026-05
- **Final completion:** 2026-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was set-up in 2017, even though the protocol was adjusted, it was not possible to find suitable patients.
- **Last updated:** 2022-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383001, "Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05383001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*